EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA
Clinical trials for EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Triple-Threat treatment trial aims to keep aggressive lung cancer at bay
Disease control OngoingThis trial is testing a combination of three drugs (niraparib, temozolomide, and atezolizumab) to see if they work better together to control advanced cancers, especially a type called extensive-stage small cell lung cancer. The study first finds a safe dose, then compares the th…
Matched conditions: EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New combo therapy aims to keep aggressive lung cancer at bay
Disease control OngoingThis study is for people with a specific type of advanced small cell lung cancer (SLFN11-positive). It tests if adding a daily pill called talazoparib to a standard immunotherapy drug (atezolizumab) is better at keeping the cancer from growing or spreading than the immunotherapy …
Matched conditions: EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 25, 2026 14:09 UTC
-
New drug combo aims to outsmart tough lung cancer
Disease control OngoingThis study is testing if adding an experimental drug called berzosertib (M6620) to standard chemotherapy (topotecan) works better than chemotherapy alone for adults whose small cell lung cancer has come back. The goal is to see if the combination can help control the cancer for l…
Matched conditions: EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
Scientists test Triple-Threat attack on Tough-to-Treat lung cancer
Disease control OngoingThis early-stage study is testing the safety and best dose of a new three-drug combination for small cell lung cancer that has returned after initial treatment. The combination includes a pill (tazemetostat), a chemotherapy (topotecan), and an immunotherapy (pembrolizumab), aimin…
Matched conditions: EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC
-
New drug aims to supercharge chemo against aggressive lung cancer
Disease control OngoingThis early-stage study is testing a new drug, LB-100, to see if it makes standard chemotherapy and immunotherapy work better against extensive-stage small cell lung cancer. The main goals are to find the safest and most effective dose of LB-100 and to check for side effects when …
Matched conditions: EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC
-
New Triple-Threat attack on aggressive lung cancer
Disease control OngoingThis study is testing a new combination of treatments for people with extensive-stage small cell lung cancer who haven't had treatment yet. It combines a targeted drug (olaparib), an immunotherapy drug (durvalumab), standard chemotherapy, and radiation. The goal is to see if this…
Matched conditions: EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC